Page 19 - Read Online

Komiya et al. J Cancer Metastasis Treat 2018;4:1 I http://dx.doi.org/10.20517/2394-4722.2017.65 Page 9 of 9

20. Highlights of prescribing information. NEXAVAR® (sorafenib). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2010/021923s008s009lbl.pdf [Last accessed on 10 Jan 2018]
21. Highlights of prescribing information. SUTENT® (sunitinib malate). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2011/021938s13s17s18lbl.pdf [Last accessed on 10 Jan 2018]
22. Highlights of prescribing information. VOTRIENT® (pazopanib). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2012/022465s-010S-012lbl.pdf [Last accessed on 10 Jan 2018]
23. Highlights of prescribing information. INLYTA® (axitinib). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2012/202324lbl.pdf [Last accessed on 10 Jan 2018]
24. Highlights of prescribing information. CYRAMZA® (ramucirumab).Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2014/125477s007lbl.pdf [Last accessed on 10 Jan 2018]
25. Highlights of prescribing information. ZALTRAP® (ziv-aflibercept).Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
label/2012/125418s000lbl.pdf [Last accessed on 10 Jan 2018]
26. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico
LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and
paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
27. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak
M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N. Phase III study of carboplatin and paclitaxel
alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42.
28. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a
potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
29. Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell
type-dependent metastasis. Cancer Lett 2012;320:48-55.
30. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors inducedby sunitinib malate are
tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007;104:17069-74.
31. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M,
Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22:21-35.
32. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated
with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol
2008;26:5326-34.
33. Schmittnaegel, M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH, Laoui D, De Palma
M. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med
2017;9:eaak9670.
34. Allen, E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G. Combined
antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 2017;9:eaak9679.
35. Kanda S, Goto K, Shiraishi H, Kubo E, Tanaka A, Utsumi H, Sunami K, Kitazono S, Mizugaki H, Horinouchi H, Fujiwara Y, Nokihara
H, Yamamoto N, Hozumi H, Tamura T. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with
advanced non-small-cell lung cancer: a four arms phase Ib study. Ann Oncol 2016;27:2242-50.
36. Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D. Carboplatin and paclitaxel with vs without bevacizumab in older patients
with advanced non-small cell lung cancer. JAMA 2012;307:1593-601.
37. Chamberlain MC, Kim BT. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J
Neurooncol 2017;133:561-9.
38. Kobari Y, Kondo T, Takagi T, Omae K, Nakazawa H, Tanabe K. Rapid progressive disease after nivolumab therapy in three patients with
metastatic renal cell carcinoma. In Vivo 2017;31:769-71.